Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HEM.Vthis companyHemostemix Inc.	CA$0.05	-3.13×	-2.96×	0×	-4.14×	-154.2%	0.0%	0.0%	0.0%	94.8%	637.9%	-30.8%	-0.72×	-0.69×	-10.05×	0.49×	0.0%	1	-454.38	2	C
BLAB.CNBritannia Life Sciences Inc.	CA$0.07	1.12×	0.7×	30.75×	-9.69×	-103.5%	8.2%	-306.8%	2753.4%	63.0%	-6.6%	-7.9%	0.01×	0.79×	-57.36×	6.57×	0.0%	6	3.03	4	A+
DOSE.CNRapid Dose Therapeutics Corp.	CA$0.11	-5.88×	-2.78×	7.19×	-15.23×	-398.4%	-34.5%	-78.3%	-122.2%	47.2%	117.1%	-1.4%	-0.74×	-3.2×	-1.78×	0.04×	0.0%	3	-27.84	2	C
MDMA.CNPharmala Biotech Holdings Inc.	CA$0.17	-6.19×	5.47×	22.2×	-6.47×	-266.4%	-139.6%	-355.6%	-359.2%	-88.5%	-87.6%	-7.8%	0×	0.02×	0×	1.71×	0.0%	2	5.56	1	D+
MRVL.VMarvel Biosciences Corp.	CA$0.11	-3.74×	-2.07×	0×	-5.38×	-160.0%	0.0%	0.0%	0.0%	55.2%	73.6%	-13.9%	-0.58×	-1.12×	-4.66×	0.08×	0.0%	2	-56.02	2	C
NARA.CNPangenomic Health Inc.	CA$0.30	-2.42×	-3.87×	0×	-2.53×	-135.1%	0.0%	0.0%	0.0%	156.8%	173.2%	-22.2%	-0.1×	-0.05×	-835.72×	0.07×	0.0%	2	-346.8	—	—
Peer median	—	-3.74×	-2.07×	7.19×	-6.47×	-160.0%	0.0%	-78.3%	0.0%	55.2%	73.6%	-7.9%	-0.1×	-0.05×	-4.66×	0.08×	0.0%	2	-27.84	2	—